Document Detail

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
MedLine Citation:
PMID:  20151157     Owner:  NLM     Status:  MEDLINE    
At present, new compounds are available to treat secondary hyperparathyroidism, namely calcimimetics, novel phosphorus binders and also novel vitamin D receptor activators. Calcimimetics increase the sensitivity of the parathyroid gland to calcium through spatial configurational changes of the calcium-sensing receptor. In addition, experimental studies have demonstrated that calcimimetics also upregulate both the calcium-sensing receptor and the vitamin D receptor. They are efficacious in children, though the experience in paediatric chronic kidney disease is still limited. Sevelamer, lanthanum carbonate and magnesium iron hydroxycarbonate are novel phosphorus binders available on the market. Several studies have demonstrated their efficacy and safety up to 6 years, though costs are the main limitation for a wider use. Since almost all the experience available on the new phosphorus binders comes from its use in adults, studies on children are needed in order to confirm the efficacy and safety of these products. Other new salts and polymers are also being developed. New vitamin D receptor activators, such as paricalcitol, are as effective at suppressing parathyroid hormone (PTH) as the traditional vitamin D receptor activators used for the past two decades, but they have a better and safer profile, showing fewer calcaemic and phosphoraemic effects while preserving the desirable effects of the vitamin D receptor activators on the cardiovascular system, hypertension, inflammation and fibrosis. Their use in children with chronic kidney disease has revealed similar responses to those of adults. The novel compounds discussed in this review should facilitate and improve the management of mineral and bone disorders in children with chronic kidney disease.
Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Related Documents :
6296847 - Development of hybridomas secreting monoclonal antibodies to the chicken intestinal 1 a...
12508107 - Functional interaction of megalin with the megalinbinding protein (megbp), a novel tetr...
15833897 - Dopamine agonist-induced yawning in rats: a dopamine d3 receptor-mediated behavior.
12901907 - Design and synthesis of potent vitamin d receptor antagonists with a-ring modifications...
6388097 - Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma...
7560077 - Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages fro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-02-12
Journal Detail:
Title:  Pediatric nephrology (Berlin, Germany)     Volume:  25     ISSN:  1432-198X     ISO Abbreviation:  Pediatr. Nephrol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-02-24     Completed Date:  2010-06-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8708728     Medline TA:  Pediatr Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  609-16     Citation Subset:  IM    
Bone and Mineral Research Unit, Instituto Reina Sofia de Investigación, REDinREN ISCIII, Hospital Universitario Central de Asturias, Universidad de Oviedo, Julián Clavería S/N, 33006 Asturias, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density Conservation Agents / therapeutic use
Calcium / metabolism,  therapeutic use*
Chelating Agents / therapeutic use
Ergocalciferols / therapeutic use
Hyperparathyroidism, Secondary / drug therapy*
Kidney Failure, Chronic / drug therapy,  metabolism
Naphthalenes / therapeutic use
Parathyroid Glands
Phosphates / metabolism*
Polyamines / therapeutic use
Protein Binding
Receptors, Calcitriol / antagonists & inhibitors*,  drug effects,  metabolism
Receptors, Calcium-Sensing / antagonists & inhibitors*,  drug effects,  metabolism
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Chelating Agents; 0/Ergocalciferols; 0/Naphthalenes; 0/Phosphates; 0/Polyamines; 0/Receptors, Calcitriol; 0/Receptors, Calcium-Sensing; 131918-61-1/paricalcitol; 182683-00-7/sevelamer; 7440-70-2/Calcium; UAZ6V7728S/cinacalcet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Should I stay or should I go: predator- and conspecific-induced hatching in a marine snail.
Next Document:  A study on strategies for improving growth and body composition after renal transplantation.